Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned an average recommendation of “Moderate Buy” from the twenty-four research firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, sixteen have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $386.1386.

Several research analysts have recently commented on the company. Truist Financial decreased their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. JPMorgan Chase & Co. dropped their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research report on Friday, July 31st. Citigroup decreased their price target on Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a research note on Monday, August 3rd. Finally, Needham & Company LLC lowered their price objective on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research report on Thursday, July 30th.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $27,000. Golden State Wealth Management LLC raised its position in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Finally, Manchester Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of ALNY opened at $236.56 on Friday. The firm has a market cap of $31.65 billion, a price-to-earnings ratio of 43.97 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The firm has a 50 day moving average price of $263.44 and a 200-day moving average price of $294.13.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s quarterly revenue was up 66.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.51) EPS. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post 6.59 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.